AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Q4 2018 Earnings Conference Call Transcript
Feb 07, 2019 • 08:00 am ET
Good morning my name is Regina and I will be your conference operator today. At this time I would like to welcome everyone to the AMAG Pharmaceuticals 2018 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks there will be a question and answer session.
It is now my pleasure to turn today's call over to Ms. Linda Lennox, Vice President, Investor Relations, you may begin your conference.
Linda S. Lennox
Thank you Regina. Good morning and welcome to the AMAG Pharmaceuticals conference call to discuss our 2018 financial results. Earlier this morning, we issued a press release. For those of you who don't have a copy, you can access it in the Investors section of our website at amagpharma.com. Please be reminded that remarks made during this call may include forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that these forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Please refer to our 2017 Form 10-K and subsequent filings with the SEC for a full review of the risks and uncertainties associated with our business.
On today's call, we will discuss certain non-GAAP financial measures with respect to our performance. We use these non-GAAP measures for financial and operational decision-making, and as a means to evaluate our performance because we believe they better represent the ongoing economics of our business. The definitions of our non-GAAP measures are set forth in our earnings press release, which was filed with the SEC today.
Copies may be obtained at sec.gov, and in the Investors section of our website. With me on today's call are Bill Heiden, our President and Chief Executive Officer; Nick Grund, our Chief Commercial Officer; Dr. Julie Krop, our Chief Medical Officer and Ted Myles, our Chief Financial Officer. Let me quickly run through the agenda for this morning's call. Bill will briefly review the accomplishments of 2018, Nick will then provide a quick update of our commercial product portfolio. Julie, will review the products that we have in development. Today, we'll be providing a bit more background on our ciraparantag programs so that everyone gets a bit more detail on this product and why we're so enthusiastic about its potential.
And then Ted will provide a review of the 2018 financials as well as looking ahead to our plans for 2019. And then we'll open up the call for Q&A.With that, it's my pleasure to now turn the call over to Bill. Bill?
William K. Heiden
Thank you Linda and good morning to all of you joining us on the phone. So let's get started with a quick review of the achievements of 2018. I won't go through each and every accomplishment listed here. It's a long list and we're proud of the progress we made last year. The two big themes for 2018 that strike me were first,